- In July 2024, Alcon Vision LLC successfully completed the acquisition of BELKIN Vision. This strategic move aims to integrate BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) technology into Alcon's portfolio, thereby enhancing its glaucoma treatment options with a new first-line therapy2. The DSLT technology has received approval from the European Union and the U.K., and it has also obtained clearance from the U.S. Food and Drug Administration (FDA)
- In September 2023, BVI acquired Medical Mix to expand its medical footprint across Europe. Medical Mix is renowned for its expertise and product offerings in medical devices for ophthalmic surgery. This strategic acquisition aims to strengthen BVI’s market position and broaden its reach across European markets, further solidifying its role in the medical and surgical device industry
- In May 2023, Bausch + Lomb and Novaliq announced that the FDA had approved their new medical solution, MIEBO (Perfluorohexyloctane Ophthalmic Solution), for treating the signs and symptoms of dry eye disease. MIEBO is the first and only prescription eye drop approved for dry eye disease that specifically addresses tear evaporation
